LONDON (Alliance News) - Life sciences company TyraTech Inc on Thursday said trading in the first half of the year has continued to be positive, with sales of its Vamousse head lice treatment rising.
TyraTech said sales of Vamousse were in line with its expectations in the six months to the end of June, though revenue from UK sales has been modestly hurt by the decline in sterling following the Brexit vote in the UK. TyraTech reports in dollars.
TyraTech added its PureScience animal health portfolio has made further progress, with three products for poultry and swine production launched at the end of the first half.
Shares in TyraTech were down 3.5% to 3.14 pence on Thursday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
